These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38145866)

  • 1. Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST).
    Gouda MA; Janku F; Wahida A; Buschhorn L; Schneeweiss A; Abdel Karim N; De Miguel Perez D; Del Re M; Russo A; Curigliano G; Rolfo C; Subbiah V
    Ann Oncol; 2024 Mar; 35(3):267-275. PubMed ID: 38145866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics.
    Lv J; Wu C; Li J; Chen F; He S; He Q; Zhou G; Ma J; Sun Y; Wei D; Lin L
    BMC Med; 2022 Aug; 20(1):268. PubMed ID: 35996151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology.
    Jakobsen AKM; Spindler KG
    Eur J Cancer; 2023 Feb; 180():180-183. PubMed ID: 36610263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers.
    Gouda MA; Huang HJ; Piha-Paul SA; Call SG; Karp DD; Fu S; Naing A; Subbiah V; Pant S; Dustin DJ; Tsimberidou AM; Hong DS; Rodon J; Meric-Bernstam F; Janku F
    JCO Precis Oncol; 2022 Jul; 6():e2100512. PubMed ID: 35834760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies.
    Abbou SD; Shulman DS; DuBois SG; Crompton BD
    Pediatr Blood Cancer; 2019 May; 66(5):e27595. PubMed ID: 30614191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.
    Heitzer E; van den Broek D; Denis MG; Hofman P; Hubank M; Mouliere F; Paz-Ares L; Schuuring E; Sültmann H; Vainer G; Verstraaten E; de Visser L; Cortinovis D
    ESMO Open; 2022 Apr; 7(2):100399. PubMed ID: 35202954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.
    Weng J; Atyah M; Zhou C; Ren N
    Clin Exp Med; 2020 Aug; 20(3):329-337. PubMed ID: 32239299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor DNA: current challenges for clinical utility.
    Dang DK; Park BH
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine.
    Rossi G; Ignatiadis M
    Cancer Res; 2019 Jun; 79(11):2798-2804. PubMed ID: 31109952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid biopsy for precision diagnostics and therapeutics.
    Anitha K; Posinasetty B; Naveen Kumari K; Chenchula S; Padmavathi R; Prakash S; Radhika C
    Clin Chim Acta; 2024 Feb; 554():117746. PubMed ID: 38151071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
    Cheng ML; Pectasides E; Hanna GJ; Parsons HA; Choudhury AD; Oxnard GR
    CA Cancer J Clin; 2021 Mar; 71(2):176-190. PubMed ID: 33165928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor DNA and liquid biopsy in oncology.
    Cescon DW; Bratman SV; Chan SM; Siu LL
    Nat Cancer; 2020 Mar; 1(3):276-290. PubMed ID: 35122035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.
    Casanova-Salas I; Athie A; Boutros PC; Del Re M; Miyamoto DT; Pienta KJ; Posadas EM; Sowalsky AG; Stenzl A; Wyatt AW; Mateo J
    Eur Urol; 2021 Jun; 79(6):762-771. PubMed ID: 33422353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
    Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
    Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of circulating tumor DNA in breast cancer.
    Zhao Y; Sheng M; Zheng L; Xiong D; Yang K; Luo Y
    Breast J; 2020 Sep; 26(9):1797-1800. PubMed ID: 32052544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.